Optimal Dose https://validator.w3.org/feed/docs/rss2.html Weekly News 24 October to 30 October 2026 Weekly News 24 October to 30 October 2026 AimedBio and Boehringer Ingelheim initiate Phase 1 study of ADC BI 4060107 Xilio Therapeutics dosed the first patient in the Phase 1/2 trial of XTX501 for metastatic NSCLC VitsGen Therapeutics receives FDA ODD for FAP-Targeted Radiopharmaceutical 177Lu-FAP-VG11 China’s NMPA accepted the application for Disitamab vedotin plus subcutaneous Toripalimab for HER2-expressing Urothelial carcinoma NMPA accepted the new indication application for sac-TMT plus pembrolizumab as 1L treatment for PD-L1-negative non-squamous NSCLC Enhertu received EU approval as adjuvant treatment for HER2-positive early Breast cancer Optimal Dose – CAR-T Digest (August 2020) Samsung Bioepis receives FDA FTD for SBE303 for the treatment of Urothelial cancer European Commission expands PADCEV + Keytruda approval to resectable MIBC, regardless of cisplatin eligibility Weekly News 17 October to 23 October 2026 Weekly News 17 October to 23 October 2026 Enhertu approved in China for previously treated patients with HER2+ metastatic Solid tumors Hansoh Pharma announces strategic collaboration and license agreement with Roche to advance novel ADC portfolio BioNTech and Gilead partner to evaluate Pumitamig plus Trodelvy in 1L TNBC Medicovestor announces FDA FTD for MC001, a FIC ADC for Pancreatic cancer Weekly News 10 October to 16 October 2026 Weekly News 10 October to 16 October 2026 MacroGenics dosed the first patient in the phase 1 trial of MGC030 for advanced Solid tumors Adlai Nortye partnered with Lilly and Merck KGaA to evaluate AN4035 in combination with cetuximab Alentis and PinotBio partnered to develop next-generation CLDN1-targeting ADCs DR30206 fusion protein received China IND approval for combination therapy in HNSCC SYS6062 ADC received clinical trial approval in China Iza-Bren combination with radiotherapy received NMPA clinical trial approval for HNSCC Weekly News 03 October to 09 October 2026 Weekly News 03 October to 09 October 2026 Enhertu approved in China for HER2-positive early Breast cancer with residual disease AstraZeneca and Daiichi Sankyo collaborate with Summit Therapeutics to evaluate Datroway plus Ivonescimab across multiple tumor types [²¹²Pb]PSV359 receives FDA Fast Track Designation for FAP-positive solitary fibrous tumors AbbVie’s Temab-A receives FDA Breakthrough Therapy Designations for CRC and NSCLC Crescent Biopharma receives FDA IND clearance for CR-002 in Solid tumors Datroway approved in China for metastatic TNBC ineligible for PD-1/PD-L1 inhibitors SEC recommends approval for additional indication of AstraZeneca’s anti-cancer drug CSPC Pharmaceutical Group has initiated phase 1/2 clinical trial of SYS6043 for the Solid tumor in China Telix Joins Thera4Care with TLX400-Tx to accelerate translation of next generation FAP-targeting theranostics Sino biopharmaceutical enters strategic oncology partnership with Boehringer Ingelheim valued at up to US$7 billion Alphamab oncology announces IND application for innovative EGFR/HER3 dual payload bispecific ADC JSKN021 was approved by the FDA NMPA grants priority review to Hengrui’s Trastuzumab Rezetecan NDA for 1L HER2-positive breast cancer Weekly News 31 October to 06 November 2026 Weekly News 31 October to 06 November 2026 Monthly Digest – November 2026 Monthly Digest – November 2026 Ifinatamab deruxtecan BLA for previously treated extensive-stage SCLC was voluntarily withdrawn in the U.S. BL-M05D1 received BTD in China for previously treated advanced Gastric/GEJ cancer Weekly News 26 September to 02 October 2026 Weekly News 26 September to 02 October 2026 Perioperative Imfinzi plus Enfortumab vedotin received U.S. FDA Priority Review for MIBC AstraZeneca announced an equity investment and clinical collaboration with Summit Therapeutics to advance ADC combinations in cancer Nurix Therapeutics announced a $7 million milestone achievement under its strategic collaboration with Pfizer